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Abstract
KSHV is found predominantly in a latent state in most cell types, impeding 
investigations of the lytic replication cycle. Here we engineered the cloned KSHV 
genome, BAC36, to enforce constitutive expression of the main lytic switch regulator, 
RTA (ORF50). The resulting virus, KSHV-lyt, activated by default the lytic cycle and 
replicated to high titers in various cells. Using KSHV-lyt we showed that ORF33 
(encoding a tegument protein) is essential for lytic KSHV replication in cell culture, 
but ORF73 (encoding the latent nuclear antigen, LANA) is not. Thus, KSHV-lyt 
should be highly useful to study viral gene function during lytic replication.
KSHV (human herpesvirus 8) is the etiologic agent of Kaposi's sarcoma and 
the B-cell-derived malignancies multicentric Castleman's disease (MCD) and primary 
effusion lymphoma (PEL) (3, 5). KSHV infects a variety of cell types in vivo, but
predominantly establishes a latent state of infection (1). During latency, the viral 
genome is maintained in the nucleus as an episome, and only few viral genes are 
expressed. Although latent infection seems to be sufficient to promote cellular 
transformation, lytic replication is also required for KS development (17) and for virus 
dissemination. The switch from latency to lytic replication is initiated by the ORF50- 
encoded replication and transcription activator (RTA) protein. The ORF50 transcript 
consists of two exons separated by an intron, which encodes on the complementary 
strand ORF49 (Fig. 1A). Splicing of ORF50 mRNA allows the expression of RTA, 
which functions as an immediate-early transcription factor capable of inducing many 
viral and cellular genes (9, 15, 20). RTA expression is both necessary and sufficient 
to induce the complete progression of KSHV through the lytic cycle (9). 
In vitro, KSHV infection is either abortive or results in latency in most cell types 
(1). Lytic replication was found to some extent after infection of primary human 
endothelial cells, but was not self-sustaining over longer periods of time (4, 7). In 
latently-infected cells, KSHV reactivation can be triggered by chemical inducers such 
as 12-O-tetradecanoylphorbol-13-acetate (TPA) or sodium butyrate (13). However, 
these chemicals are quite toxic and can cause unwanted side effects (6). 
Alternatively, enforced RTA expression in trans by a plasmid or viral vector can be 
used to drive KSHV lytic replication (1). However, these systems are not self- 
sustaining, and replication stops when the inducing stimulus is withdrawn. Here we 
describe the construction and characterization of a recombinant KSHV carrying an 
intronless ORF50 gene under the control of a constitutively active promoter. The 
recombinant virus enters by default the lytic replication cycle in different cell types 
without the need for further induction. Infected cells display cytopathic effect (CPE), 
produce expanding foci, express all kinetic classes of viral genes, and release 
considerable amounts of virus progeny into the supernatant. We further show that 
this lytically replicating KSHV can be used to analyze viral gene function during lytic 
replication. 
A KSHV genome derived from the PEL cell line BCBL1 has been cloned as a 
bacterial artificial chromosome (termed BAC36) in E.coli, making it amenable to 
bacterial mutagenesis techniques (26). We used BAC36 to construct a lytically 
replicating KSHV clone. First we replaced ORF50 exon 1 and ORF49 (nt 71110 to 
72093 in BAC36, GenBank accession# HQ404500) by homologous recombination 
using   a   zeocin    resistance   cassette    PCR-amplified   with    primers   5'- 
CAACCTTACTCCGCAAGGGGTAGTCTGTTGTGAGAATACTGTCCAGGCAGTCAAGTCCT 
GCTCCTCCTCGGCCA-3' and 5'-CCGAGAGGCCGACGAAGCTTTCCACACAGGACCGC 
CGAAGCTTCTTACCCTTGTTGACAATTAATCATCGGCA-3' essentially as described 
(21).  The resulting  BAC was termed KSHVA49 (Fig.  1A).  For the second 
recombination step, a helper plasmid was constructed. It contained ORF49, a 
kanamycin resistence (kan) marker, and ORF50 exon 1, and 50 nt flanking 
sequences for homologous  recombination.  Briefly,  two  oligonucleotides   
(5'-GATCTCCACCATGGCGCAAGATGACAAGGGTAAGAAGCTTCGGCGGTCCTGTGTGGAA 
AGCTTCGTCGGCCTCTCGGGCC-3' and 5'-GGCCGCAACCTTACTCCGCAAGGGGTAG 
TCTGTTGTGAGAATACTGTCCAGGCAG-3') were inserted into pReplacer (11) between 
the Bglll and Apal sites and NotI and EcoRI sites, respectively. Then, ORF49 was 
PCR-amplified and inserted between BamHI and EcoRI sites. A kan marker flanked 
by FLP recombination target (FRT) sites was introduced at the EcoRI site. The 
recombination cassette was excised with NotI and ApaI from the helper plasmid and 
used to modify KSHVA49 (Fig. 1A). Finally, the kan marker was removed with FLP 
recombinase yielding KSHV-lyt, in which an intronless ORF50 gene is driven by a 
cellular phosphoglycerate kinase (pgk) promoter. All constructs were analyzed by 
restriction digest and gel electrophoresis (Fig. 1B), by PCR, and by sequencing the 
relevant regions (data not shown). 
Transfection of BAC  DNA into telomerase-immortalized  retinal pigment 
epithelial cells (hTERT-RPE1, ATCC CRL-4000) was monitored by expression of 
GFP, which is encoded adjacent to the BAC cassette (26). Transfection of KSHV-lyt 
resulted in the development of morphologically distinct foci of GFP-expressing cells 
(Fig. 2A), suggesting that KSHV-lyt-derived virus was able to cause CPE and spread 
to neighboring cells without any further exogenous stimulus. Foci increased in size 
and number over time until the entire monolayer was infected. By contrast, the 
parental BAC36 did not spread and did not form foci. After transfer of supernatant 
from infected cells to fresh RPE1 cells, new foci appeared, even if the supernatant 
was passed through a 0.45 urn filter. 
By the same three-step procedure outlined in figure 1A we also constructed 
KSHV-lyt[-49]. ORF49 was not re-inserted in the second recombination step, but 
otherwise KSHV-lyt[-49] was constructed analogously to KSHV-lyt. KSHV-lyt[-49] 
formed foci and replicated in RPE1 like KSHV-lyt (data not shown), indicating that 
ORF49 is not required for KSHV lytic replication. However, since a previous study 
has shown that ORF49 cooperates with RTA to activate several KSHV lytic 
promoters (8), we decided to continue further work only with KSHV-lyt. 
Surprisingly, serial passaging of KSHV-lyt virus resulted in a loss of GFP 
expression within the first 2-3 passages (Fig. 2B). KSHV virion DNA was recovered 
from supernatants of infected RPE1 cells and analyzed by restriction digest. 
Compared to KSHV-lyt BAC DNA, the virion DNA lacked the region containing the 
BAC cassette (Fig. 2C, D), suggesting that the BAC replicon and the adjacent GFP 
expression cassette were lost during virus reconstitution and lytic replication. In an 
attempt to avoid the loss of GFP expression, we constructed a modified version of 
KSHV-lyt, in which the BAC cassette contained a Cre recombinase gene and was 
flanked with loxP sites to make it self-excising. Such a procedure has been used 
previously for other herpesvirus BACs (19, 24). The GFP gene was kept outside of 
the loxP-flanked region in order to preserve GFP expression after excision of the 
BAC replicon. Much to our chagrin, this modification did not prevent loss of GFP 
expression during virus reconstitution (data not shown). When we further investigated 
the underlying reason for this phenomenon, we found out that the region, in which 
the BAC cassette was inserted, was duplicated in the parental BAC36. The second 
copy of the region ranging approximately from ORF K5 to ORF19 is located within 
the terminal repeats (TRs) and contains the BAC cassette (data not shown). While 
this work was in progress, an analysis of the complete BAC36 sequence was 
published by others (23). The paper identified and documented the same duplication 
that we had observed. Hence, we did not further investigate this property of BAC36. 
However, the presence of the BAC cassette within the duplicated region within the 
TR region offers a rational explanation for the rapid loss of the BAC cassette and the 
GFP gene. In fact, a recent publication suggested that the TRs are a suitable location 
for insertion of the BAC cassette because it will be automatically excised upon virus 
reconstitution by terminal repeat-mediated homologous recombination (25). 
RPE1 cells were used routinely for virus reconstitution from BAC DNA and for 
titration of infectious KSHV. They have an intact contact inhibition response and 
tolerate the prolonged culturing required to recover replicating virus after BAC 
transfection. RPE1 cells were also the preferred cell type for titration because they 
developed the clearest CPE and showed most reliable and reproducible results. Viral 
titers (focus-forming units) were determined using the median tissue culture infective 
dose (TCID50) method (16). Larger quantities of infectious virus were grown on RPE1 
cells and harvested from the supernatants of infected cells. High-titer KSHV-lyt 
stocks were obtained by pelleting the virus (180 min at 27000 g) and resuspending it 
in a smaller volume of complete medium. To determine the replication capability of 
KSHV-lyt, growth kinetics were determined on different cells. RPE1, Vero (ATCC 
CRL-1587D) and primary HUVEC (Lonza, Switzerland) were infected at an MOI of 
0.02 using 5 ug/ml polybrene and centrifugal enhancement of infection (30 min at 
900 g). On all cell lines used here, KSHV-lyt infection lead to cell rounding and 
swelling, release of infectious virions into the supernatant, and finally cell demise 
several days after infection. After low-MOI infection, the virus replicated to maximum 
titers of about 105 TCID50/ml in RPE1 cells. 
Next we tested whether KSHV-lyt can be used to determine the importance of 
viral genes for lytic replication. First we replaced ORF33, encoding a tegument 
protein (27) by a galK/kan cassette with methods described previously (18). In a 
second step, galK/kan was removed by homologous recombination using a synthetic 
oligonucleotide (5'-GCTATAGGGCGTCGAAGGAGGATCTGGTGTTCATTCGAGGCCGCT 
ATGGCTAGCAGCATGTTGCGCACATCAGCGAGCTGGACCGTCCTCCGGGTCGCGT-3') 
generating the seamless deletion mutant KSHV-lytA33. The revertant virus, Rev33, 
was obtained by replacing galK/kan with a PCR-amplified ORF33 sequence (Fig. 
3A). Mutant BACs were checked by restriction digest (Fig. 3B) and transfected into 
RPE1 cells (Fig. 3C). As expected, both parental and revertant BACs yielded 
infectious virus that replicated to comparable titers (Fig. 3D). The A33 deletion 
mutants (with or without galK/kan) repeatedly failed to reconstitute infectious virus, 
indicating that ORF33 is essential for lytic replication. This result matches similar 
findings in the related y-herpesvirus MHV-68, for which ORF33 is also essential for 
replication (10). 
The LANA-encoding ORF73 was deleted by a similar approach (Fig. 4A). 
ORF73 was first replaced with galKlkan, yielding KSHV-lytA73. Then, a cloned KSHV 
fragment containing ORF73 and approximately 150 nt of flanking KSHV sequence 
(kindly provided by Rolf Renne) was used to generate the revertant Rev73. LANA 
expression from the recombinant KSHVs was checked by immunofluorescence (Fig. 
4B) and immunoblot (Fig. 4C). As the cloned ORF73 sequence used for Rev73 was 
derived from a different KSHV clone and contained fewer internal repeats, Rev73- 
expressed LANA was slightly smaller in size than that of the parental virus. All three 
recombinant viruses expressed RTA and K8.1 proteins in infected RPE1 cells (Fig. 
4C), demonstrating that LANA expression is not essential for KSHV lytic replication. 
However, the A73 mutant grew to slightly lower titers than the parental and revertant 
viruses, indicating that LANA might contribute directly or indirectly to lytic virus 
production (Fig. 4D).  In contrast,  LANA-deficient KSHV BAC36 and Rhesus 
Rhadinovirus  showed increased virus production in previous studies, which was 
attributed to the loss of LANA-mediated repression of the RTA promoter (14, 22). 
This repression is probably absent in KSHV-lyt, as RTA expression is driven by a 
heterologous promoter. 
In summary, we demonstrated that a molecular KSHV clone modified to 
express RTA constitutively replicates to substantial titers in cultured cells. The 
lytically replicating KSHV is well-suited to study viral gene function during lytic 
replication. Another promising application for lytically replicating KSHV is the field of 
antiviral drug testing. Most of the available antiherpesviral drugs target the lytic 
replication phase (12, 17) and are, therefore, difficult to test with previously available 
systems in which KSHV is predominantly latent (2). Of course, PEL cell lines and 
unmodified BAC36 remain the systems of choice for investigating latency and 
reactivation. 
We thank Shou-Jiang Gao for the BAC36, Gary Hayward and Keji Ueda for 
antibodies, Thomas Schulz and Cornelia Henke-Gendo for sharing the BAC36 
sequence before publication, and Antonio Gallo and Adam Grundhoff for a critical 
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Figures
Figure 1. Construction of KSHV-lyt. (A) Schematic illustration of KSHV BAC36 mutagenesis. 
ORF50 exon 1 and ORF49 were first replaced by a zeo cassette. Then, ORF49 was 
re-inserted in reverse orientation together with a pgk promoter and ORF 50 exon 1. 
The kan cassette flanked by FRT sites (black ovals) was subsequently removed with 
FLP recombinase. Nt positions refer to GenBank HQ404500. (B) XbaI restriction 
pattern of the parental and mutant BAC genomes in an ethidium bromide-stained 
agarose gel. For better visibility, images of the upper and lower parts of the gel were 
taken separately. Fragments affected by mutagenesis as predicted in panel A are 
indicated by arrow heads.  
Figure 2. Analysis of KSHV-lyt replication. (A) Virus reconstitution following BAC transfection 
into RPE1 cells. GFP expression and focus formation was observed by fluorescence 
microscopy over time. Images were taken 2 and 8 days post transfection (dpt). (B) 
Focus formation 8 days after transfering infected cell supernatant onto fresh RPE1 
cells. (C) Comparison of KSHV-lyt BAC and virion DNA. Equal amounts of DNA were 
digested with PmeI or XhoI and analyzed by gel electrophoresis. Fragments 
representing the BAC cassette are indicated by arrow heads. Asterisks indicate 
additional differences. (D) The PmeI and XhoI restriction maps with the expected 
fragments in the BAC cassette region are depicted. (E) Replication of KSHV-lyt on 
different cells after low MOI infection. Titers (focus-forming units) were determined on 
RPE1 cells using the TCID50 method. DL, detection limit. 
Figure 3. ORF33 is required for KSHV-lyt lytic replication. (A) Genomic organization of KSHV- 
lyt ORF33  mutants.  Nt positions refer to GenBank HQ404500.  (B) Acc65I 
(isoschizomer of KpnI) restriction pattern of the parental and mutant BAC genomes in 
an ethidium bromide-stained agarose gel. The relevant fragments (see panel A) are 
indicated by arrow heads. (C) RPE1 cells were transfected with recombinant BAC 
genomes as indicated, and GFP fluorescence was observed 10 days post 
transfection. (D) RPE1 cells were infected at an MOI of 0.02 TCID50/cell of the 
indicated  viruses.   Infectious  virus  (focus-forming   units)   released   into  the 
supernatants was titrated on RPE1 cells. DL, detection limit.  
Figure 4. ORF73 is dispensable for KSHV-lyt lytic replication. (A) Genomic organization of 
KSHV-lyt ORF73 mutants. Nt positions refer to GenBank HQ404500. (B) RPE1 cells 
were infected as indicated and analyzed by immunofluorescence. RTA was stained 
with a rabbit antiserum (kindly provided by Gary Hayward), and AlexaFluor488- 
coupled anti-rabbit IgG (Invitrogen, Germany). LANA was visualized with mouse anti- 
LANA (Acris, Germany) and AlexaFluor568-coupled anti-mouse IgG. Nuclei were 
counterstained with DAPI. (C) Viral protein expression in infected RPE1 cells was 
analyzed by immunoblot with the same primary antibodies as above, or anti-K8.1 
(Santa Cruz, CA) and peroxidase-coupled secondary antibodies (DAKO, Germany). 
(D) RPE1 cells were infected at an MOI of 0.005 TCID50/cell, and viral titers (focus- 
forming units) in the supernatant were determined. DL, detection limit.
